OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 23,535 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) by 29.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 102,784 shares of the company’s stock after buying an additional 23,535 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.33% of Acrivon Therapeutics worth $619,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Acorn Capital Advisors LLC bought a new stake in Acrivon Therapeutics during the 4th quarter valued at $2,440,000. Northern Trust Corp lifted its stake in shares of Acrivon Therapeutics by 11.3% during the 4th quarter. Northern Trust Corp now owns 117,323 shares of the company’s stock worth $706,000 after purchasing an additional 11,925 shares during the last quarter. Renaissance Technologies LLC boosted its position in Acrivon Therapeutics by 7.6% during the fourth quarter. Renaissance Technologies LLC now owns 49,400 shares of the company’s stock valued at $297,000 after purchasing an additional 3,500 shares in the last quarter. Barclays PLC boosted its position in Acrivon Therapeutics by 14.4% during the fourth quarter. Barclays PLC now owns 38,091 shares of the company’s stock valued at $228,000 after purchasing an additional 4,785 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Acrivon Therapeutics by 20.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 37,063 shares of the company’s stock valued at $223,000 after purchasing an additional 6,239 shares during the last quarter. Institutional investors own 71.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on ACRV shares. KeyCorp initiated coverage on shares of Acrivon Therapeutics in a research report on Friday, January 31st. They set an “overweight” rating for the company. Piper Sandler assumed coverage on shares of Acrivon Therapeutics in a research note on Monday, May 5th. They set an “overweight” rating and a $6.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Acrivon Therapeutics in a research note on Wednesday, March 26th. Finally, HC Wainwright cut their price target on shares of Acrivon Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Wednesday, March 26th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Acrivon Therapeutics currently has a consensus rating of “Buy” and an average price target of $19.17.

Insider Transactions at Acrivon Therapeutics

In other news, major shareholder Perceptive Advisors Llc sold 1,054,669 shares of the firm’s stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $1.95, for a total value of $2,056,604.55. Following the completion of the transaction, the insider now directly owns 4,306,189 shares in the company, valued at $8,397,068.55. This trade represents a 19.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last ninety days, insiders sold 1,707,833 shares of company stock worth $3,009,858. Company insiders own 11.90% of the company’s stock.

Acrivon Therapeutics Stock Performance

Shares of ACRV stock opened at $1.13 on Wednesday. Acrivon Therapeutics, Inc. has a fifty-two week low of $1.13 and a fifty-two week high of $10.16. The firm has a market capitalization of $35.43 million, a price-to-earnings ratio of -0.42 and a beta of 1.88. The stock’s 50-day simple moving average is $2.62 and its 200-day simple moving average is $5.10.

Acrivon Therapeutics (NASDAQ:ACRV) last released its earnings results on Thursday, March 27th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.09. As a group, equities analysts forecast that Acrivon Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.